NCT03284957
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have ER+ tumor(s)
Exclusions: Patients with known brain metastases 
https://ClinicalTrials.gov/show/NCT03284957